Jahns-Streubel G, Reuter C, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W
Department of Hematology and Oncology, Georg-August-University, Göttingen, Germany.
Leukemia. 1995 Nov;9(11):1857-63.
The current study was undertaken to determine the relevance of leukemic blast cell proliferative activity, cellular parameters of Ara-C metabolism and the in vitro sensitivity to GM-CSF in association with the clinical response to TAD-9 induction therapy in 66 patients with de novo acute myeloid leukemia (AML). Proliferative activity was assessed by 3H-thymidine (3H-TdR) incorporation and thymidine kinase (TK) activity, parameters of Ara-C metabolism comprised the activities of deoxycytidine kinase (DCK) and DNA polymerase alpha (poly alpha) as well as Ara-CTP concentrations and 3H-Ara-C uptake into DNA. GM-CSF sensitivity was determined by in vitro incubation of blasts for 48 h with or without GM-CSF (100 U/ml) followed by an additional 4 h concurrent exposure to GM-CSF and 3H-TdR (0.5 microCi/ml). The following results were obtained as expressed by median values and ranges: 3H-TdR incorporation: 1.07 pmol/10(5) cells (0.0-10.1), TK: 7.3 pmol/min/mg protein (1.3-56.0), DCK: 9.3 pmol/min/mg protein (0.77-47.1), poly alpha: 1.7 pmol/min/mg protein (0.00-28.9), Ara-CTP: 53.3 ng/10(7) cells (13.3-211.0), 3H-Ara-C uptake: 0.06 pmol/10(5) cells (0.0-0.57). 3H-Ara-C uptake was correlated with 3H-TdR incorporation (r = 0.74) and with the (S-phase dependent) activities of TK (r = 0.73) and poly alpha (r = 0.71, but not with DCK activity or intracellular Ara-CTP content. Blast cells of 37 from 55 analyzed patients were found to be sensitive to GM-CSF stimulation as defined by an increase in 3H-TdR incorporation > or = 1.5-fold over control values after the 48 h GM-CSF exposure. In vitro data were related with clinical response to TAD-9 induction therapy in 43 patients with newly diagnosed AML, taking the blast cell reduction at day 10 or 16 to < 5% or > or = 5% residual blasts as early parameter for adequate or inadequate response, respectively. While neither 3H-Ara-C uptake, nor intracellular Ara-CTP concentration, TK nor DCK activity were predictive for response, a high 3H-TdR incorporation and a high poly alpha activity were associated with adequate blast cell reduction. Median values of 3H-TdR incorporation were 2.26 pmol/10(5) cells for patients with adequate blast cell clearance and 0.80 pmol/10(5) cells for patients with inadequate blast cell clearance (P = 0.11), the respective values for poly alpha were 3.22 pmol/min/mg protein for responders and 1.1 pmol/min/mg protein for non-responders (P = 0.0085).(ABSTRACT TRUNCATED AT 400 WORDS)
本研究旨在确定66例初发急性髓系白血病(AML)患者白血病原始细胞增殖活性、阿糖胞苷(Ara-C)代谢的细胞参数以及体外对粒细胞-巨噬细胞集落刺激因子(GM-CSF)的敏感性与TAD-9诱导治疗临床反应的相关性。通过³H-胸腺嘧啶核苷(³H-TdR)掺入和胸苷激酶(TK)活性评估增殖活性,Ara-C代谢参数包括脱氧胞苷激酶(DCK)和DNA聚合酶α(多聚α)的活性以及Ara-CTP浓度和³H-Ara-C掺入DNA的情况。通过将原始细胞在有或无GM-CSF(100 U/ml)的条件下体外培养48小时,然后再额外4小时同时暴露于GM-CSF和³H-TdR(0.5 μCi/ml)来测定GM-CSF敏感性。以下结果以中位数和范围表示:³H-TdR掺入:1.07 pmol/10⁵细胞(0.0 - 10.1),TK:7.3 pmol/分钟/毫克蛋白(1.3 - 56.0),DCK:9.3 pmol/分钟/毫克蛋白(0.77 - 47.1),多聚α:1.7 pmol/分钟/毫克蛋白(0.00 - 28.9),Ara-CTP:53.3 ng/10⁷细胞(13.3 - 211.0),³H-Ara-C摄取:0.06 pmol/10⁵细胞(0.0 - 0.57)。³H-Ara-C摄取与³H-TdR掺入相关(r = 0.74),与TK(r = 0.73)和多聚α(r = 0.71)的(S期依赖性)活性相关,但与DCK活性或细胞内Ara-CTP含量无关。在55例分析患者中,37例患者的原始细胞被发现对GM-CSF刺激敏感,定义为在48小时GM-CSF暴露后³H-TdR掺入增加≥1.5倍于对照值。将新诊断AML的43例患者体外数据与TAD-9诱导治疗的临床反应相关联,分别以第10天或16天原始细胞减少至<5%或≥5%残留原始细胞作为反应充分或不充分的早期参数。虽然³H-Ara-C摄取、细胞内Ara-CTP浓度、TK或DCK活性均不能预测反应,但高³H-TdR掺入和高多聚α活性与原始细胞充分减少相关。原始细胞清除充分的患者³H-TdR掺入中位数为2.26 pmol/10⁵细胞,原始细胞清除不充分的患者为0.80 pmol/10⁵细胞(P = 0.11),反应者多聚α的相应值为3.22 pmol/分钟/毫克蛋白,无反应者为1.1 pmol/分钟/毫克蛋白(P = 0.0085)。(摘要截断于400字)